Paragon 28

Paragon 28, Inc. engages in operation of an orthopedic foot and ankle company. Its products include bone graft harvest system, bone marrow aspirate kits, and soft tissue fixation system. The company was founded by Albert DaCosta, Frank Bono, Jim Riegler and Lee Rosenthal in 2010 and is headquartered in Englewood, CO.

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Paragon 28 reports strong revenue growth and strategic initiatives outlook

Paragon 28 delivered robust financial results in Q4 2022 and full-year 2022, driven by strong revenue growth in the U.S. and international markets.
While facing challenges in achieving profitability and commercializing new technologies, the company's focus on innovation and market expansion presents opportunities for future growth.
With a solid liquidity position and strategic initiatives in place, Paragon 28 is well-positioned to capitalize on market opportunities and drive continued performance.
Investors can look forward to the company's projected revenue growth in 2023 and advancements in technology adoption for improved patient outcomes.

Paragon 28 reports record Q1 revenue, eyes global growth opportunities

Paragon 28 delivered robust financial performance in Q1 2023, driven by strong revenue growth in the U.S. and internationally. While challenges in achieving profitability persist, the company's strategic focus on product development and global market expansion positions it for continued success. Opportunities for growth include optimizing sales force efficiency, launching new products, and capitalizing on international market strength.

Paragon 28 reports strong Q2 performance, eyes international expansion

Paragon 28's Q2 2023 earnings call reflects robust financial performance, driven by international growth and successful product launches.
While facing supply chain challenges and anticipating a growth slowdown, the company remains focused on expanding its market reach and product offerings.
Investments in key markets and a strategic focus on emerging growth drivers underscore Paragon 28's commitment to sustained revenue growth.
Prudence in guidance and operational planning amidst uncertainties highlights the company's proactive approach to managing challenges and seizing opportunities.

Paragon 28 reports steady Q3 growth amidst supply chain challenges

Paragon 28's Q3 2023 earnings call highlighted steady revenue growth, product innovation, and strategic investments driving performance.
While facing supply chain challenges and billing day impacts, the company's focus on market-specific strategies and surgeon training remains a strength.
Securing a new credit facility and reaffirming revenue guidance underscore Paragon 28's commitment to future growth and market leadership.

Paragon 28 reports robust Q4 performance, eyes growth in 2024

Paragon 28's strong performance in Q4 2023, coupled with expectations for growth in 2024, positions the company well for the future. Despite challenges like supply chain issues, the company's focus on innovation and market expansion presents significant opportunities. By maintaining accountability and leveraging market opportunities, Paragon 28 aims to drive continued success.

Paragon 28 reports record Q1 revenue, eyes growth opportunities

Paragon 28's Q1 2024 performance reflects strong revenue growth and strategic product launches.
While facing challenges like negative cash flow and increased SG&A expenses, the company remains optimistic.
Opportunities lie in upcoming product launches, market expansion, and engagement with investors.
Overall, Paragon 28's resilience and growth trajectory position it well for future success in the medical devices sector.

Paragon 28 reports record revenue and positive EBITDA in Q3

Paragon 28's Q3 2024 performance reflects strong revenue growth, product innovation, and a milestone in positive adjusted EBITDA post-IPO.
The company's emphasis on operational efficiency and cost optimization positions it well for sustained profitability and growth.
While facing challenges in cash flow and margin stabilization, Paragon 28 has opportunities to capitalize on its strengths and drive further expansion.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

ENGLEWOOD, Colo.--(BUSINESS WIRE)--Paragon 28, Inc. (NYSE: FNA), (the “Company”) a leader in foot and ankle surgical solutions, today announced the appointment of Dave Demski to serve as an independent director of the Company, effective immediately. Mr. Demski brings a wealth of global orthopedic expertise, with over two decades of executive leadership experience. With the addition of Mr. Demski, the Company increased the size of its Board of Directors from eight members to nine members and has.

Paragon 28 Appoints Dave Demski to Board of Directors

Adaptive Biotechnologies

Newamsterdam Pharma Co NV

As of Dec. 11, 2024, three stocks in the health care sector could be flashing a real warning to investors who value momentum as a key criteria in their trading decisions.

Top 3 Health Care Stocks That May Collapse This Quarter

The consensus price target hints at a 39.7% upside potential for Paragon 28, Inc. (FNA). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

Wall Street Analysts Predict a 39.67% Upside in Paragon 28, Inc. (FNA): Here's What You Should Know

NEW YORK , Dec. 2, 2024 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Paragon 28, Inc. ("Paragon 28, Inc." or the "Company") (NYSE: FNA) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Paragon 28, Inc. investors who were adversely affected by alleged securities fraud between May 5, 2023 and September 20, 2024.

Levi & Korsinsky Announces the Filing of a Securities Class Action on Behalf of Paragon 28, Inc.(FNA) Shareholders

NEW YORK, NY / ACCESSWIRE / November 29, 2024 / If you suffered a loss on your Paragon 28, Inc. (NYSE:FNA) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/paragon-28-inc-lawsuit-submission-form?prid=114144&wire=1 or contact Joseph E. Levi, Esq.

Paragon 28, Inc. Class Action: Levi & Korsinsky Reminds Paragon 28, Inc. Investors of the Pending Class Action Lawsuit With a Lead Plaintiff Deadline of November 29, 2024 - FNA

NEW YORK, Nov. 29, 2024 (GLOBE NEWSWIRE) -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Paragon 28, Inc. (“Paragon 28” or “the Company”) (NYSE: FNA) and certain of its officers.

FNA INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Paragon 28, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit

NEW YORK, NY / ACCESSWIRE / November 29, 2024 / If you suffered a loss on your Paragon 28, Inc. (NYSE:FNA) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/paragon-28-inc-lawsuit-submission-form?prid=114103&wire=1 or contact Joseph E. Levi, Esq.

Investors who Lost Money on Paragon 28, Inc. (FNA) Should Contact Levi & Korsinsky About Pending Class Action - FNA

LOS ANGELES, CA / ACCESSWIRE / November 29, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Paragon 28, Inc. ("Paragon 28" or "the Company") (NYSE:FNA) for violations of 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's securities between May 5, 2023 and August 8, 2024, inclusive (the "Class Period"), are encouraged to contact the firm before November 29, 2024.

Deadline TODAY: The Schall Law Firm Invites Investors To Reach Out About Taking Part In A Lawsuit Against Paragon 28, Inc.

LOS ANGELES--(BUSINESS WIRE)--FNA Investors Have Opportunity to Lead Paragon 28, Inc. Securities Fraud Lawsuit with the Schall Law Firm.

FNA Investors Have Opportunity to Lead Paragon 28, Inc. Securities Fraud Lawsuit with the Schall Law Firm

NEW YORK, NY / ACCESSWIRE / November 29, 2024 / If you suffered a loss on your Paragon 28, Inc. (NYSE:FNA) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/paragon-28-inc-lawsuit-submission-form?prid=114040&wire=1 or contact Joseph E. Levi, Esq.

Class Action Filed Against Paragon 28, Inc. (FNA) - November 29, 2024 Deadline to Join - Contact Levi & Korsinsky

NEW YORK, NY / ACCESSWIRE / November 29, 2024 / If you suffered a loss on your Paragon 28, Inc. (NYSE:FNA) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/paragon-28-inc-lawsuit-submission-form?prid=114037&wire=1 or contact Joseph E. Levi, Esq.

Shareholders that lost money on Paragon 28, Inc.(FNA) should contact Levi & Korsinsky about pending Class Action - FNA

NEW YORK , Nov. 29, 2024 /PRNewswire/ --  Why: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of Paragon 28, Inc. (NYSE: FNA) between May 5, 2023 and September 20, 2024, both dates inclusive (the "Class Period"), and those who purchased Paragon 28 call options or sold put options during the Class Period, of the November 29, 2024 lead plaintiff deadline in the securities class action first filed by the Firm. So what: If you purchased Paragon 28 securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.

FNA Deadline: FNA Investors with Losses in Excess of $100K Have Opportunity to Lead Paragon 28, Inc. Securities Fraud Lawsuit First Filed by The Rosen Law Firm

NEW YORK CITY, NY / ACCESSWIRE / November 29, 2024 / Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Paragon 28, Inc. ("Paragon 28" or "the Company") (NYSE:FNA) and certain of its officers. Class Definition This lawsuit seeks to recover damages against Defendants for alleged violations of the federal securities laws on behalf of all persons and entities that purchased or otherwise acquired Paragon 28 securities between May 5, 2023 through September 20, 2024, inclusive (the "Class Period").

FINAL REMINDER FNA DEADLINE: Bronstein, Gewirtz & Grossman LLC Alerts Paragon 28, Inc. Investors to Participate in the Class Action Lawsuit

NEW YORK, NY / ACCESSWIRE / November 28, 2024 / If you suffered a loss on your Paragon 28, Inc. (NYSE:FNA) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/paragon-28-inc-lawsuit-submission-form?prid=113998&wire=1 or contact Joseph E. Levi, Esq.

FNA LAWSUIT ALERT: Levi & Korsinsky Notifies Paragon 28, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline

NEW YORK, NY / ACCESSWIRE / November 28, 2024 / If you suffered a loss on your Paragon 28, Inc. (NYSE:FNA) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/paragon-28-inc-lawsuit-submission-form?prid=113984&wire=1 or contact Joseph E. Levi, Esq.

Levi & Korsinsky Reminds Paragon 28, Inc. Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of November 29, 2024 - FNA

NEW YORK, NY / ACCESSWIRE / November 28, 2024 / If you suffered a loss on your Paragon 28, Inc. (NYSE:FNA) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/paragon-28-inc-lawsuit-submission-form?prid=113961&wire=1 or contact Joseph E. Levi, Esq.

Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of November 29, 2024 in Paragon 28, Inc. Lawsuit - FNA

LOS ANGELES, CA / ACCESSWIRE / November 28, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Paragon 28, Inc. ("Paragon 28" or "the Company") (NYSE:FNA) for violations of 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's securities between May 5, 2023 and August 8, 2024, inclusive (the "Class Period"), are encouraged to contact the firm before November 29, 2024.

DEADLINE TOMORROW: Shareholders With Losses Are Urged To Join The Schall Law Firm In A Securities Fraud Case Against Paragon 28 Inc

NEW YORK, NY / ACCESSWIRE / November 28, 2024 / If you suffered a loss on your Paragon 28, Inc. (NYSE:FNA) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/paragon-28-inc-lawsuit-submission-form?prid=113920&wire=1 or contact Joseph E. Levi, Esq.

Levi & Korsinsky Announces the Filing of a Securities Class Action on Behalf of Paragon 28, Inc. (FNA) Shareholders

NEW YORK CITY, NY / ACCESSWIRE / November 28, 2024 / Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Paragon 28, Inc. ("Paragon 28" or "the Company") (NYSE:FNA) and certain of its officers. Class Definition This lawsuit seeks to recover damages against Defendants for alleged violations of the federal securities laws on behalf of all persons and entities that purchased or otherwise acquired Paragon 28 securities between May 5, 2023 through September 20, 2024, inclusive (the "Class Period").

FINAL FNA DEADLINE: Bronstein, Gewirtz & Grossman LLC Reminds Paragon 28, Inc. Investors to Join the Class Action Lawsuit

NEW YORK, NY / ACCESSWIRE / November 27, 2024 / If you suffered a loss on your Paragon 28, Inc. (NYSE:FNA) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/paragon-28-inc-lawsuit-submission-form?prid=113900&wire=1 or contact Joseph E. Levi, Esq.

Paragon 28, Inc. Sued for Securities Law Violations - Investors Should Contact Levi & Korsinsky Before November 29, 2024 to Discuss Your Rights - FNA

NEW YORK, NY / ACCESSWIRE / November 27, 2024 / If you suffered a loss on your Paragon 28, Inc. (NYSE:FNA) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/paragon-28-inc-lawsuit-submission-form?prid=113886&wire=1 or contact Joseph E. Levi, Esq.

Investors who lost money on Paragon 28, Inc.(FNA) should contact Levi & Korsinsky about pending Class Action - FNA

Investors can contact the law firm at no cost to learn more about recovering their losses

Paragon 28, Inc. Investors: Please contact the Portnoy Law Firm to recover your losses. November 29, 2024 Deadline to file Lead Plaintiff Motion.

NEW YORK, NY / ACCESSWIRE / November 27, 2024 / If you suffered a loss on your Paragon 28, Inc. (NYSE:FNA) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/paragon-28-inc-lawsuit-submission-form?prid=113861&wire=1 or contact Joseph E. Levi, Esq.

Lost Money on Paragon 28, Inc. (FNA)? Join Class Action Suit Seeking Recovery - Contact Levi & Korsinsky

NEW YORK, NY / ACCESSWIRE / November 27, 2024 / If you suffered a loss on your Paragon 28, Inc. (NYSE:FNA) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/paragon-28-inc-lawsuit-submission-form?prid=113859&wire=1 or contact Joseph E. Levi, Esq.

Shareholders that lost money on Paragon 28, Inc. (FNA) Urged to Join Class Action - Contact Levi & Korsinsky to Learn More

LOS ANGELES, CA / ACCESSWIRE / November 27, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Paragon 28, Inc. ("Paragon 28" or "the Company") (NYSE:FNA) for violations of 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's securities between May 5, 2023 and August 8, 2024, inclusive (the "Class Period"), are encouraged to contact the firm before November 29, 2024.

News for Paragon 28 Stock (FNA)